reason report
bottom line friday host svb leerink med-tech
leadership seri call inc manag michael carrel
presid ceo andrew wade svp cfo given
share pressur sinc announc
sentreheart acquisit manag took opportun highlight
strateg natur deal deal appar
court year manag also discuss growth outlook
atrc open ablat busi expect upcom approv
converg procedur overal call reinforc view
sentreheart acquisit fit within compani commit
build full portfolio product address two-third atrial
fibril af patient persist long-standing persist
limit effect therapi option avail today top
continu believ core busi support sustain
double-digit growth profil forese futur upcom
converg mi launch late like meaning
acceler growth longer term key takeaway call
acquisit sentreheart strateg financi
sound move given lariat expand product offer
electrophysiologist ep could highli complementari
atrc converg ablat procedur manag
view deal structur call option mileston payment
repres value-cr catalyst addit
read-through converg trial posit neg
atrc manag blind data manag
indic core open ablat busi make
sale repres sustain high-single-digit growth
opportun forese futur increas awar
ramp train effort continu drive ablat penetr
open cardiac procedur notabl cabg coronari arteri
bypass graft largest market opportun also least
penetr approv manag believ converg
acceler growth drive sustain double-digit mi growth longer
reiter op pt next month believ
share trade appli ev/sal multipl
revenu estim assum stabl multipl
current level ev/our estim still modest
discount smid-cap med-tech coverag univers avdr mp
op op mp op op ev/
sale given sale growth acceler march
toward profit think ev/sal multipl justifi
net debt total capit
medic suppli devic
sale
year price history/av daili volume mil
compani inform svb leerink llc research
revenu non-gaap adjust dilut ep
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
rate share outperform price target
believ well-posit sustain double-digit top-lin growth least
next year compani core open ablat busi -- make
sale -- well-posit deliv sustain mid-single-digit growth forese futur
penetr ramp beyond guidelin chang acceler
continu advanc mi minim invas ablat pipelin could ultim
open multibillion-dollar atrial fibril af ablat market opportun address
atrial fibril patient
ceo carrel appear commit compani current long-term growth strategi
penetr concomit open-heart surgic ablat market expand mi surgic
ablat drive atriclip sale cross-sel expand intern
near term manag work ensur limited-to-no sale forc disrupt compani
continu focu penetr svb leerink estim global concomit
surgic ablat market -- less penetr today compani success
advanc clinic trial initi converg frost deep progress
bottom line friday host svb leerink med-tech leadership seri call
inc manag michael carrel presid ceo andi wade svp cfo
given share pressur sinc announc sentreheart
acquisit manag took opportun highlight strateg natur deal deal
appar court year manag also discuss growth
outlook atrc open ablat busi upcom approv converg
procedur overal call reinforc view sentreheart acquisit fit within
compani commit build full portfolio product address
two-third atrial fibril af patient persist long-standing persist
limit effect therapi option avail today top
continu believ core busi support sustain double-digit growth profil
forese futur upcom converg mi launch late
like meaning acceler growth longer term
key takeaway call
acquisit sentreheart strateg financi sound move given
lariat expand product offer electrophysiologist ep could
highli complementari atrc converg ablat procedur manag view
deal structur call option mileston payment repres value-cr
catalyst addit read-through converg trial posit
neg atrc manag blind data
manag indic core open ablat busi make
sale repres sustain high-single-digit growth opportun forese futur
increas awar ramp train effort continu drive ablat penetr
open cardiac procedur notabl cabg coronari arteri bypass graft
largest market opportun also least penetr
approv manag believ converg acceler growth drive
sentreheart strateg sound financi accret acquisit
open call manag confid discuss recent acquisit
sentreheart privat held develop percutan left atrial appendag manag
solut asset kept eye past five year given share
pressur sinc announc sentreheart accus
manag point strateg financi posit deal investor seem
strateg addit atrc product offer
sentreheart acquisit expand product offer electrophysiologist ep
could highli complementari atrc converg ablat
procedur hybrid procedur perform cardiac surgeon
electrophysiologist lariat sutur deliveri devic complementari compani
current product seek advanc atrc competit posit af market lariat
expand total address market deliv product hand ep
vs current call point cardiac surgeon lariat help address still rel
unmet need increasingli physician want close appendag
sentreheart lariat cannib atriclip compet bsx op
watchman directli manag think lariat direct competit
bsx op watchman given differ patient popul lariat address patient
afib atrial fibril gener appendag area someth around af
start base appendag watchman indic treat patient afib
increas risk bleed anticoagul also manag emphas
addit lariat cannib sale exist atriclip product
atriclip place cardiac surgeon vs lariat use ep
manag view deal structur value-cr call option
manag view deal structur call option mileston payment
repres value-cr catalyst given deal structur up-front
cash common stock plu addit base amaz clinic trial pma
approv base reimburs mileston manag believ deal
structur highli accret mileston payment repres posit
catalyst potenti increas valu compani patient enrol
amaz trial manag expect clinic data pma approv late
sustain double-digit growth busi adopt ramp
core open ablat busi make sale repres
sustain high-single-digit growth opportun least view forese
futur focus drive ablat penetr open cardiac procedur call
manag walk us current penetr growth outlook open ablat
market segment open ablat market consist three distinct procedur
cabg largest market opportun open ablat open procedur
manag estim penetr
savr surgic aortic valv replac manag estim
savr procedur everi year patient undergo savr repres
afib
mitral valv surgeri smallest market opportun open ablat
highest penetr rate base manag estim encouragingli
manag note kol mitral space push adopt
current level us suggest signific runway growth even
highest penetr segment
continu help drive ramp adopt under-penetrated cabg market
releas new clamp easier place thu like attract basic
cabg procedur beyond open ablat busi manag also see
sustain double-digit growth within core atriclip overal grow awar
benefit close appendag
increas awar ramp train effort continu drive adopt
manag also address barrier adopt compani plan clear
hurdl increas awar benefit treat af patient -- short
term long termperform better overal treat ramp effort train
cours could increas physician comfort also drive better outcom thu
converg drive sustain double-digit growth upon approv
approv manag believ converg acceler growth drive
sustain double-digit mi growth longer term regard timelin manag note
converg trial near complet follow-up plan submit
modul end manag expect releas data head
anticip fda panel meet fda approv like time-frame
next month believ share trade appli
ev/sal multipl revenu estim assum stabl multipl
current level ev/our estim still modest discount
smidcap med-tech coverag univers avdr
ev/sal given sale growth acceler march toward profit
think ev/sal multipl justifi
risk includ failur success execut surgeon train new af indic
drive slower-than-expect revenu ramp slow open heart procedur growth and/
adopt concomit surgic ablat clinic trial delay failur demonstr
superior converg trial ou regulatori delay
dollar million except per share amount
product sold
research develop expens
cog sale
sg sale
 sale
oper expens sale
compani report svb leerink estim
object studi establish safeti effect
dual epicardi endocardi ablat procedur patient present
persist atrial fibril long-standing persist atrial
fibril util atricur bipolar system atriclip laa
exclus system endoscop open ablat procedur follow
endocardi map ablat procedur util commerci
avail rf base irrig power control ablat cathet
endocardi lesion endocardi procedur stage occur
day post epicardi surgic procedur
deep af trial expect landmark trial patient
-a feb trial still paus work fda incorpor
risk mitig protocol trial expect resum sometim
-receiv fda approv move forward
-a apr start re-enrol continu work fda obtain final
clearanc move toward full enrol
-a feb receiv fda approv expand deep af clinic trial
includ addit patient
 announc first patient enrol
freedom document af atrial flutter atrial tachycardia last
second durat month follow-up visit absenc class
aad except previous fail time frame month post
endocarid ablat procedur month follow-up visit
wade note manag stretch goal full enrol end
enrol complet like
 oct converg patient enrol sever new site
come line improv pace enrol
 feb site enrol patient enrol
 may patient enrol site run
acceler process
 jul site enrol patient enrol
 nov site enrol patient enrol expect
patient enrol end
 feb site enrol patient enrol expect
complet enrol
 apr site enrol patient enrol expect
complet enrol
 aug patient enrol
-complet enrol auguest patient
last patient follow-up septemb data like releas right fda
af/at/atri flutter free absent class aad except previous fail
intoler class aad increas dosag time frame month
primari efficaci endpoint success failur af/at/afl free absent class
aad except previous fail intoler class aad
increas dosag follow month blank period month post
plan releas converg data around anticip fda penal meet
-first patient enrol oct frost patient enrol
 nov reach halfway mark enrol patient
 feb near complet patient enrol expect
complet
 nov feb track complet enrol near futur
visual analogu scale va pain surgic region time frame post-
treatment persist atrial
object random pivot studi evalu safeti
efficaci epi-sense-af guid coagul
visitrax treatment symptomat persist atrial fibril af
patient refractori intoler least one class class anti-
arrhythm drug aad subject us ou site
primari efficaci endpoint success failur af/at/afl free
absent class aad except previous fail intoler class
aad increas dosag follow blank
period post procedur follow-up visit
primari safeti endpoint incid major advers event
mae list protocol subject undergo converg
procedur procedur post procedur time period
thorac procedur
frost trial evalu effect cryoanalgesia pain
manag cardiac procedur involv thoracotomi expect
clinic data improv treatment afib futur
design trial prospect random trial includ total
patient random includ patient
treatment arm intraop cryoablat plu soc
patient control arm soc alon studi includ patient
undergo unilater thoracotomi cardiac procedur evalu
pain score lung function recoveri hospit stay
epicardi percutan
repeat cathet ablat
persist long-standing
prospect random multicent trial investig
optim treatment persist long-standing persist af refer
radiofrequ rf ablat studi object compar
efficaci safeti two intervent approach prevent
recurr af symptomat drug refractori patient persist
atricur cryoic lesion
persist long-stand
cryoic ablat studi ablat cardiac
tissu surgeri treatment persist long-stand
persist atrial fibril open concomit cardiac surgeri
effect devic demonstr establish
devic effect elimin persist long-stand persist
atrial fibril clinic signific proport treat patient
studi prospect multicent random control studi
evalu safeti effect lariat system
percutan isol ligat left atrial appendag left
atrium adjunct plan pulmonari vein isol pvi cathet
ablat treatment subject symptomat persist
studi conduct two stage
limit earli stage stage subject site
complet transit stage
pivot stage/ phase stage subject site
enrol subject stage includ primari
adjunct pvi
persist long-standing
on-go plan enrol patient
number subject free document atrial fibril af atrial flutter
atrial tachycardia episod second durat month follow-up
absenc class antiarrhythm drug aad time frame
month post endocardi procedur hybrid procedur last allow cathet
 plan enrol patient center studi enrol patient
persist long-stand persist atrial fibril undergo cardiac surgic
procedur heart valv repair replac and/or coronari arteri bypass
 februari announc first patient treat trial
primari effect endpoint freedom af/afl/at last second
durat follow ablat procedur absenc class
post-procedur death death procedur relat
 plan enrol patient center
 patient enrol full enrol anticip
 freedom episod atrial fibril second month post index
 freedom atrial fibrillation/atri tachycardia/atri flutter recurr defin
episod second without aad month follow-up
 composit endpoint stroke caus system embol adjud
clinic event committe month follow-up
